ANN ARBOR STAGE III HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE III HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to keep hodgkin lymphoma at bay longer
Disease control OngoingThis study compares two different immunotherapy drugs (nivolumab or brentuximab vedotin) given together with standard chemotherapy for people aged 12 and older who have newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination works better a…
Matched conditions: ANN ARBOR STAGE III HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:20 UTC
-
New hope for older hodgkin patients: Chemo-Free combo shows promise
Disease control OngoingThis study tests a combination of two drugs, nivolumab and brentuximab vedotin, in people aged 60 and older (or younger people who cannot tolerate standard chemotherapy) with untreated Hodgkin lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer witho…
Matched conditions: ANN ARBOR STAGE III HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 26, 2026 10:06 UTC